rosiglitazone has been researched along with Hyperplasia in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (7.69) | 18.2507 |
| 2000's | 7 (53.85) | 29.6817 |
| 2010's | 4 (30.77) | 24.3611 |
| 2020's | 1 (7.69) | 2.80 |
| Authors | Studies |
|---|---|
| Fryklund, C; Morén, B; Neuhaus, M; Periwal, V; Stenkula, KG | 1 |
| Cho, HJ; Jin, S; Kang, HJ; Kim, BK; Kim, HS; Kim, JY; Kwon, YW; Lee, HY; Lee, JE; Oh, BH; Park, YB; Yang, HM | 1 |
| Cho, HJ; Hur, J; Kang, HJ; Kim, HS; Kim, SH; Kim, TY; Kwon, YW; Lee, CS; Park, KW; Park, YB; Yang, HM | 1 |
| Brugaletta, S; García-García, HM; Garg, S; Huang, C; Kolatkar, NS; Kravitz, BG; Miller, DM; Morocutti, G; Nesto, RW; Ratner, RE; Serruys, PW | 1 |
| Fang, CQ; Gao, CY; Gao, D; Li, JC; Wang, JZ; Wang, YJ; Xiang, J; Yao, GE; Zhang, LL | 1 |
| Atmaca, S; Bagrıyanık, A; Guzeloglu, M; Hazan, E; Reel, B | 1 |
| Desouza, CV; Diez, J; Dunne, B; Fonseca, VA; Matta, AS; McNamara, DB; Murthy, SN | 1 |
| Al-Omran, M; Cherng, WJ; Ciliberti, N; Fedak, PW; Li, RK; Li, SH; Stanford, WL; Szmitko, PE; Verma, S; Wang, CH; Weisel, RD | 1 |
| Kaposzta, Z; Kaski, JC; Markus, HS; Sidhu, JS | 1 |
| Atkinson, RD; Lee, JW; Lytle, C; Straus, DS; Tod, TJ; Vo, KT | 1 |
| Agrawal, KC; Chattergoon, NN; Diez, JG; Dunne, JB; Fonseca, NA; Fonseca, VA; Jeter, JR; Kadowitz, PJ; McNamara, DB; Mondal, D; Murthy, SN; Obregon, DF | 1 |
| Bonacci, JV; Fernandes, DJ; Quan, L; Stewart, AG; Taylor, CC; Ward, JE | 1 |
| Brown, HR; Brown, KK; Graves, RA; Jennermann, C; Kliewer, SA; Lehmann, JM; MacGinnitie, MA; Morris, DC; Oliver, BB; Tai, TA; Wilkison, WO | 1 |
2 trial(s) available for rosiglitazone and Hyperplasia
| Article | Year |
|---|---|
Evaluation of in-stent restenosis in the APPROACH trial (Assessment on the Prevention of Progression by Rosiglitazone On Atherosclerosis in diabetes patients with Cardiovascular History).
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Angioplasty, Balloon, Coronary; Coronary Angiography; Coronary Artery Disease; Coronary Restenosis; Coronary Vessels; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Drug-Eluting Stents; Female; Glipizide; Humans; Hyperplasia; Hypoglycemic Agents; Male; Metals; Middle Aged; Neointima; Predictive Value of Tests; Prospective Studies; Prosthesis Design; Rosiglitazone; Stents; Thiazolidinediones; Time Factors; Treatment Outcome; Ultrasonography, Interventional | 2012 |
Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients without diabetes mellitus.
Topics: Adrenergic beta-Antagonists; Aged; Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Carotid Artery Diseases; Carotid Artery, Common; Cohort Studies; Coronary Artery Disease; Disease Progression; Double-Blind Method; Drug Synergism; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperplasia; Insulin Resistance; Lipids; Male; Middle Aged; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazolidinediones; Transcription Factors; Ultrasonography; Weight Gain | 2004 |
11 other study(ies) available for rosiglitazone and Hyperplasia
| Article | Year |
|---|---|
Rosiglitazone treatment enhances intracellular actin dynamics and glucose transport in hypertrophic adipocytes.
Topics: Actins; Adipocytes; Animals; Glucose; Hyperplasia; Hypertrophy; Hypoglycemic Agents; Insulin; Male; Mice; Mice, Inbred C57BL; PPAR gamma; Rosiglitazone; Thiazolidinediones | 2022 |
PPARγ modulates vascular smooth muscle cell phenotype via a protein kinase G-dependent pathway and reduces neointimal hyperplasia after vascular injury.
Topics: Animals; Aorta; Calcium-Binding Proteins; Calponins; Cell Proliferation; Cyclic GMP; Cyclic GMP-Dependent Protein Kinases; Hyperplasia; Microfilament Proteins; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Nitric Oxide; PPAR gamma; Promoter Regions, Genetic; Rats; Rats, Sprague-Dawley; Rosiglitazone; Sp1 Transcription Factor; Thiazolidinediones; Thrombospondins; Tunica Intima; Vascular System Injuries | 2013 |
New mechanism of rosiglitazone to reduce neointimal hyperplasia: activation of glycogen synthase kinase-3beta followed by inhibition of MMP-9.
Topics: Animals; Apoptosis; Carotid Artery Injuries; Cell Movement; Cell Proliferation; Cell Survival; Cells, Cultured; Disease Models, Animal; Dose-Response Relationship, Drug; Enzyme Activation; Enzyme Activators; Extracellular Signal-Regulated MAP Kinases; Gene Transfer Techniques; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Hyperplasia; Matrix Metalloproteinase 9; Matrix Metalloproteinase Inhibitors; Mice; Mice, Knockout; Muscle, Smooth, Vascular; Mutation; Myocytes, Smooth Muscle; NF-kappa B; Protease Inhibitors; Rats; Rats, Sprague-Dawley; Rosiglitazone; Signal Transduction; Thiazolidinediones; Tunica Intima | 2009 |
PPARγ attenuates intimal hyperplasia by inhibiting TLR4-mediated inflammation in vascular smooth muscle cells.
Topics: Animals; Carotid Artery Injuries; Cell Movement; Cell Proliferation; Cells, Cultured; Disaccharides; Disease Models, Animal; Hyperplasia; Inflammation; Lipopolysaccharides; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Platelet-Derived Growth Factor; PPAR gamma; RNA Interference; Rosiglitazone; Sugar Phosphates; Thiazolidinediones; Toll-Like Receptor 4; Transfection; Tunica Intima | 2011 |
The effects of PPARγ agonist rosiglitazone on neointimal hyperplasia in rabbit carotid anastomosis model.
Topics: Analysis of Variance; Anastomosis, Surgical; Animals; Cardiac Surgical Procedures; Carotid Arteries; Chi-Square Distribution; Female; Hyperplasia; Immunohistochemistry; Male; Matrix Metalloproteinases; Neointima; PPAR gamma; Rabbits; Rosiglitazone; Statistics, Nonparametric; Thiazolidinediones | 2012 |
Differential effects of peroxisome proliferator activator receptor-alpha and gamma ligands on intimal hyperplasia after balloon catheter-induced vascular injury in Zucker rats.
Topics: Animals; Biomarkers; Blood Glucose; Body Weight; Catheterization; Cholesterol; Diabetes Mellitus, Type 2; Disease Models, Animal; Female; Fenofibrate; Hyperplasia; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Ligands; Models, Cardiovascular; Rats; Rats, Zucker; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazolidinediones; Transcription Factors; Triglycerides; Tunica Intima | 2003 |
Rosiglitazone facilitates angiogenic progenitor cell differentiation toward endothelial lineage: a new paradigm in glitazone pleiotropy.
Topics: Angioplasty; Animals; Arterial Occlusive Diseases; Bone Marrow Transplantation; Cell Differentiation; Cell Lineage; Cells, Cultured; Colony-Forming Units Assay; Culture Media, Conditioned; Endothelial Cells; Endothelium, Vascular; Femoral Artery; Humans; Hyperplasia; Male; Mesenchymal Stem Cells; Mice; Mice, Inbred C57BL; Multipotent Stem Cells; Muscle Cells; Muscle, Smooth, Vascular; Neovascularization, Physiologic; Radiation Chimera; Receptors, Cytoplasmic and Nuclear; Recombinant Proteins; Rosiglitazone; Thiazolidinediones; Transcription Factors; Tunica Intima; Vascular Endothelial Growth Factor A | 2004 |
The peroxisome proliferator-activated receptor gamma ligand rosiglitazone delays the onset of inflammatory bowel disease in mice with interleukin 10 deficiency.
Topics: Animals; Cytokines; Disease Models, Animal; Disease Progression; Female; Gene Expression Regulation; Hyperplasia; Hypoglycemic Agents; Inflammatory Bowel Diseases; Interleukin-10; Male; Mice; PPAR gamma; Rosiglitazone; Thiazolidinediones | 2005 |
Rosiglitazone reduces serum homocysteine levels, smooth muscle proliferation, and intimal hyperplasia in Sprague-Dawley rats fed a high methionine diet.
Topics: Animals; Carotid Arteries; Catheterization; Cell Division; Cystathionine beta-Synthase; Diet; DNA; Female; Homocysteine; Hyperplasia; Ligands; Liver; Methionine; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; PPAR gamma; Rats; Rats, Sprague-Dawley; Rosiglitazone; Thiazolidinediones; Tunica Intima | 2005 |
The PPARgamma ligand, rosiglitazone, reduces airways hyperresponsiveness in a murine model of allergen-induced inflammation.
Topics: Allergens; Animals; Bronchoalveolar Lavage Fluid; Bronchoconstrictor Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Goblet Cells; Guinea Pigs; Hyperplasia; In Vitro Techniques; Injections, Intraperitoneal; Ligands; Matrix Metalloproteinase 2; Methacholine Chloride; Mice; Mice, Inbred C57BL; Muscle Contraction; Ovalbumin; Pneumonia; PPAR gamma; Respiratory Hypersensitivity; Rosiglitazone; Thiazolidinediones; Time Factors; Trachea; Vasodilator Agents | 2006 |
Activation of the nuclear receptor peroxisome proliferator-activated receptor gamma promotes brown adipocyte differentiation.
Topics: Adipocytes; Adipose Tissue, Brown; Carrier Proteins; Cell Differentiation; Cell Line; Gene Expression Regulation; Hyperplasia; Hypoglycemic Agents; Ion Channels; Membrane Proteins; Mitochondrial Proteins; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Uncoupling Protein 1 | 1996 |